EB Pharma has executed an agreement with Janssen Pharmaceutica for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage back-up compound.
EB Pharma is conducting clinical studies in patients infected with Hepatitis Delta Virus (HDV) and will assess the efficacy and tolerability of tipifarnib as a potential new therapy.
Searching for more deal information? Current Partnering offers the following options:
|
For further deal information visit Current Agreements (subscription required)
Related
Scorecard: Top partnering deals by value in 2014
View: Top pharmaceutical companies
View: Top biotech companies
Report: Top 50 Big Pharma Partnering and M&A Deal Trends
Report: Top 50 Big Biotech Partnering and M&A Deal Trends